363 related articles for article (PubMed ID: 30368626)
1. A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.
Cai Y; Wang F; Liu Q; Li Z; Li D; Sun Z
Invest New Drugs; 2019 Oct; 37(5):799-809. PubMed ID: 30368626
[TBL] [Abstract][Full Text] [Related]
2. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
3. A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.
Chien MH; Chang WM; Lee WJ; Chang YC; Lai TC; Chan DV; Sharma R; Lin YF; Hsiao M
Mol Cancer Ther; 2017 Jun; 16(6):1102-1113. PubMed ID: 28292939
[TBL] [Abstract][Full Text] [Related]
4. Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Hirai M; Kitahara H; Kobayashi Y; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Int J Oncol; 2017 Jan; 50(1):41-48. PubMed ID: 27922697
[TBL] [Abstract][Full Text] [Related]
5. Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Monteiro de Oliveira Novaes JA; Hirz T; Guijarro I; Nilsson M; Pisegna MA; Poteete A; Barsoumian HB; Fradette JJ; Chen LN; Gibbons DL; Tian X; Wang J; Myers JN; McArthur MJ; Bell D; William WN; Heymach JV
Cancer Prev Res (Phila); 2021 Mar; 14(3):313-324. PubMed ID: 33277316
[TBL] [Abstract][Full Text] [Related]
6. PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Wang J; Xie T; Wang B; William WN; Heymach JV; El-Naggar AK; Myers JN; Caulin C
Cancer Prev Res (Phila); 2017 Dec; 10(12):684-693. PubMed ID: 29018057
[TBL] [Abstract][Full Text] [Related]
7. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Maruse Y; Kawano S; Jinno T; Matsubara R; Goto Y; Kaneko N; Sakamoto T; Hashiguchi Y; Moriyama M; Toyoshima T; Kitamura R; Tanaka H; Oobu K; Kiyoshima T; Nakamura S
Int J Oral Maxillofac Surg; 2018 Jul; 47(7):836-845. PubMed ID: 29395669
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
9. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
10. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.
Zhang T; Song X; Xu L; Ma J; Zhang Y; Gong W; Zhang Y; Zhou X; Wang Z; Wang Y; Shi Y; Bai H; Liu N; Yang X; Cui X; Cao Y; Liu Q; Song J; Li Y; Tang Z; Guo M; Wang L; Li K
Cancer Immunol Immunother; 2018 Jul; 67(7):1079-1090. PubMed ID: 29687231
[TBL] [Abstract][Full Text] [Related]
11. The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma.
Feng X; Luo Q; Zhang H; Wang H; Chen W; Meng G; Chen F
J Exp Clin Cancer Res; 2017 Jun; 36(1):81. PubMed ID: 28637493
[TBL] [Abstract][Full Text] [Related]
12. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA induces cell death via Beclin-1-dependent autophagy in oral squamous cell carcinoma SCC-9 cell line.
Qiu Y; Li C; Wang Q; Zeng X; Ji P
Cancer Med; 2018 Feb; 7(2):397-407. PubMed ID: 29316373
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade prevents the progression of oral carcinogenesis.
Dong Y; Wang Z; Mao F; Cai L; Dan H; Jiang L; Zeng X; Li T; Zhou Y; Chen Q
Carcinogenesis; 2021 Jun; 42(6):891-902. PubMed ID: 33993220
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Growth Inhibition by Afatinib and Trametinib in Preclinical Oral Squamous Cell Carcinoma Models.
Yee PS; Zainal NS; Gan CP; Lee BKB; Mun KS; Abraham MT; Ismail SM; Abdul Rahman ZA; Patel V; Cheong SC
Target Oncol; 2019 Apr; 14(2):223-235. PubMed ID: 30806895
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Yang CY; Tsao CH; Hsieh CC; Lin CK; Lin CS; Li YH; Chang WC; Cheng JC; Lin GJ; Sytwu HK; Wang YL; Chen YW
PLoS One; 2020; 15(7):e0236101. PubMed ID: 32678829
[TBL] [Abstract][Full Text] [Related]
17. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Kouketsu A; Sato I; Oikawa M; Shimizu Y; Saito H; Takahashi T; Kumamoto H
J Craniomaxillofac Surg; 2019 Jan; 47(1):33-40. PubMed ID: 30466788
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
[TBL] [Abstract][Full Text] [Related]
19. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
